R&D Costs and Productivity in Biopharmaceuticals

Frederic Michael Scherer

Scholarly Articles from Harvard Kennedy School of Government

Abstract: This article characterizes the activities required to launch a new pharmaceutical molecule into the market, summarizes studies that have attempted to pinpoint the research and development costs incurred per approved new molecule, and analyzes the various critiques levied against published R&D cost estimates. It finds that by any reckoning, R&D costs per approved molecule have risen sharply over time, most likely at a rate of approximately 7 percent per year after stripping out the effects of general economic inflation.

Date: 2011
New Economics Papers: this item is included in nep-eff and nep-ino
References: Add references at CitEc
Citations: View citations in EconPapers (7)

Published in HKS Faculty Research Working Paper Series

Downloads: (external link)
http://dash.harvard.edu/bitstream/handle/1/5688848/RWP11-046_Scherer.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hrv:hksfac:5688848

Access Statistics for this paper

More papers in Scholarly Articles from Harvard Kennedy School of Government Contact information at EDIRC.
Bibliographic data for series maintained by Office for Scholarly Communication ().